Prevalence of HLA-B*5701 in major European ethnotypes [ Designated as safety issue: No ]

Original Secondary Outcome Measures ICMJE

Not Provided

Current Other Outcome Measures ICMJE

Not Provided

Original Other Outcome Measures ICMJE

Not Provided

Descriptive Information

Brief Title ICMJE

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients

Official Title ICMJE

Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected Patients

Brief Summary

This study is a cross-sectional observational study to evaluate the prevalence of HLA-B*5701 in the European area and in major European ethnotypes.

Any HIV-1 infected patient will be eligible for this study including treatment naïve and experienced patients, as well as patients previously tested for HLA-B*5701. Patients will be approached during a standard clinic visit, and will be consented prior to any study specific procedure. They will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B*5701 status by local and central laboratories.

In selected sites patients may be asked to provide an additional blood sample. This sample will be used to develop and validate different methodologies for assessing HLA-B*5701 status.

Detailed Description

Not Provided

Study Type ICMJE

Observational

Study Design ICMJE

Observational Model: CohortTime Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Probability Sample

Study Population

HIV-1 infected adults, out patients department

Condition ICMJE

Infection, Human Immunodeficiency Virus I

HIV Infection

HIV-1 Infection

Intervention ICMJE

Procedure: Cheek cells sample

Cheek cells sample

Procedure: Blood sample

Blood sample

Study Group/Cohort (s)

HIV-1 infected adults

HIV-1 infected adults

Interventions:

Procedure: Cheek cells sample

Procedure: Blood sample

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.